Ceramedix

Ceramedix is a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies that target the sphingolipid rheostat to treat life-threatening conditions involving microvascular damage. The company's lead candidate, 2A2, is a proprietary humanized anti-ceramide antibody designed to inhibit ceramide-mediated endothelial cell apoptosis and microvascular collapse. This mechanism has broad therapeutic potential in treating Acute Radiation Syndrome (ARS), inflammatory diseases like sepsis, and radiation-induced tissue damage. Founded on research from Memorial Sloan Kettering Cancer Center, Ceramedix has secured significant non-dilutive funding from federal agencies such as BARDA and the NIH. The company aims to provide critical medical countermeasures for radiological emergencies while addressing major unmet needs in critical care and oncology.